CN104918919A - 取代的反向嘧啶Bmi-1抑制剂 - Google Patents

取代的反向嘧啶Bmi-1抑制剂 Download PDF

Info

Publication number
CN104918919A
CN104918919A CN201380070973.6A CN201380070973A CN104918919A CN 104918919 A CN104918919 A CN 104918919A CN 201380070973 A CN201380070973 A CN 201380070973A CN 104918919 A CN104918919 A CN 104918919A
Authority
CN
China
Prior art keywords
diamine
pyrimidine
fluoro
benzimidazol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380070973.6A
Other languages
English (en)
Chinese (zh)
Inventor
C-S.李
R.拜亚齐托夫
L.曹
T.W.戴维斯
W.杜
R.刘
Y.蒙
S.D.佩奇
任洪玉
N.塞多伦科
R.G.维尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Priority to CN202010080540.0A priority Critical patent/CN111423417B/zh
Publication of CN104918919A publication Critical patent/CN104918919A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
CN201380070973.6A 2012-11-21 2013-11-21 取代的反向嘧啶Bmi-1抑制剂 Pending CN104918919A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010080540.0A CN111423417B (zh) 2012-11-21 2013-11-21 取代的反向嘧啶Bmi-1抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
US61/728907 2012-11-21
PCT/US2013/071132 WO2014081906A2 (en) 2012-11-21 2013-11-21 Substituted reverse pyrimidine bmi-1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010080540.0A Division CN111423417B (zh) 2012-11-21 2013-11-21 取代的反向嘧啶Bmi-1抑制剂

Publications (1)

Publication Number Publication Date
CN104918919A true CN104918919A (zh) 2015-09-16

Family

ID=50776672

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380070973.6A Pending CN104918919A (zh) 2012-11-21 2013-11-21 取代的反向嘧啶Bmi-1抑制剂
CN202010080540.0A Active CN111423417B (zh) 2012-11-21 2013-11-21 取代的反向嘧啶Bmi-1抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010080540.0A Active CN111423417B (zh) 2012-11-21 2013-11-21 取代的反向嘧啶Bmi-1抑制剂

Country Status (32)

Country Link
US (3) US10428050B2 (cg-RX-API-DMAC7.html)
EP (1) EP2922828B1 (cg-RX-API-DMAC7.html)
JP (3) JP6412503B2 (cg-RX-API-DMAC7.html)
KR (4) KR102275676B1 (cg-RX-API-DMAC7.html)
CN (2) CN104918919A (cg-RX-API-DMAC7.html)
AR (1) AR093579A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013348009C1 (cg-RX-API-DMAC7.html)
BR (1) BR112015011760B1 (cg-RX-API-DMAC7.html)
CA (1) CA2892045C (cg-RX-API-DMAC7.html)
CL (1) CL2015001377A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150294A (cg-RX-API-DMAC7.html)
CU (1) CU24387B1 (cg-RX-API-DMAC7.html)
DK (1) DK2922828T3 (cg-RX-API-DMAC7.html)
EA (2) EA031405B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP15019948A (cg-RX-API-DMAC7.html)
ES (1) ES2821529T3 (cg-RX-API-DMAC7.html)
HK (1) HK1215032A1 (cg-RX-API-DMAC7.html)
IL (2) IL238871B (cg-RX-API-DMAC7.html)
MA (1) MA38208B1 (cg-RX-API-DMAC7.html)
MX (2) MX385385B (cg-RX-API-DMAC7.html)
NI (1) NI201500072A (cg-RX-API-DMAC7.html)
NZ (2) NZ746607A (cg-RX-API-DMAC7.html)
PE (1) PE20151413A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501130B1 (cg-RX-API-DMAC7.html)
PL (1) PL2922828T3 (cg-RX-API-DMAC7.html)
PT (1) PT2922828T (cg-RX-API-DMAC7.html)
SA (1) SA517381847B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201503982XA (cg-RX-API-DMAC7.html)
TW (1) TWI623531B (cg-RX-API-DMAC7.html)
UA (1) UA118094C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014081906A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503642B (cg-RX-API-DMAC7.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602775A (zh) * 2016-01-14 2018-09-28 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
CN109988172A (zh) * 2019-01-10 2019-07-09 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
WO2020200209A1 (zh) * 2019-04-02 2020-10-08 成都海创药业有限公司 芳香胺类化合物及其在制备ar和brd4双重抑制剂和调控剂中的用途
CN113710670A (zh) * 2019-02-28 2021-11-26 Ptc医疗公司 治疗多发性骨髓瘤的方法
CN113784757A (zh) * 2019-01-15 2021-12-10 Ptc医疗公司 治疗急性髓性白血病的方法
CN113853374A (zh) * 2019-03-11 2021-12-28 Ptc医疗公司 具有增强的生物利用度的化合物形式及其制剂
CN114096537A (zh) * 2019-03-27 2022-02-25 Ptc医疗公司 肉瘤治疗方法的有用组合

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ746607A (en) * 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
CN105593215B (zh) * 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
WO2017027709A1 (en) 2015-08-11 2017-02-16 Cognoa, Inc. Methods and apparatus to determine developmental progress with artificial intelligence and user input
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
EP3539033B1 (en) 2016-11-14 2024-10-02 Cognoa, Inc. Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability
CA3053245A1 (en) * 2017-02-09 2018-08-16 Cognoa, Inc. Platform and system for digital personalized medicine
EP3664803A4 (en) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
EP3836932A2 (en) * 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
KR102785528B1 (ko) 2019-03-22 2025-03-21 코그노아, 인크. 개인 맞춤식 디지털 치료 방법 및 디바이스
AU2020343020A1 (en) 2019-09-06 2022-03-31 Cognoa, Inc. Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978055A (en) * 1973-09-20 1976-08-31 Delalande S.A. Arylamino pyrimidinic derivatives
CN1155281A (zh) * 1994-08-13 1997-07-23 株式会社柳韩洋行 新的嘧啶衍生物及其制备方法
CN1349528A (zh) * 1999-03-06 2002-05-15 阿斯特拉曾尼卡有限公司 嘧啶化合物
CN1429222A (zh) * 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
US20040043388A1 (en) * 2001-03-02 2004-03-04 Come Jon H. Three hybrid assay system
US20040097503A1 (en) * 2000-12-12 2004-05-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
WO2010002985A1 (en) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
CN101679432A (zh) * 2006-10-19 2010-03-24 西格诺药品有限公司 杂芳基化合物、其组合物及其作为蛋白激酶抑制剂的用途
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
WO2011121418A1 (en) * 2010-03-31 2011-10-06 Palobiofarma, S.L. 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
WO2012050884A2 (en) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
WO2012078777A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188411B (cg-RX-API-DMAC7.html) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
AU7922900A (en) 1999-10-27 2001-05-08 Novartis Ag Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
CN100355751C (zh) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HK1054393B (en) 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
JP2004515550A (ja) 2000-12-15 2004-05-27 グラクソ グループ リミテッド 治療用化合物
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ES2316546T3 (es) 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
ATE337312T1 (de) 2001-07-03 2006-09-15 Vertex Pharma Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
US7109204B2 (en) 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003075828A2 (en) 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
WO2003099811A1 (en) 2002-05-23 2003-12-04 Cytopia Pty Ltd Kinase inhibitors
ES2337995T3 (es) 2002-06-28 2010-05-03 Nippon Shinyaku Co., Ltd. Derivado de amida.
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
EP1551842A1 (en) 2002-10-15 2005-07-13 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
DK1704145T3 (da) 2004-01-12 2012-09-24 Ym Biosciences Australia Pty Selektive kinaseinhibitorer
US20070117818A1 (en) 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
ES2364340T3 (es) * 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
BRPI0607062A2 (pt) 2005-02-28 2009-08-04 Japan Tobacco Inc composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
US20110098301A1 (en) 2005-03-10 2011-04-28 Bayer Healthcare Llc Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders
US20080039450A1 (en) 2006-06-22 2008-02-14 Jensen Annika J Compounds
JP2010505794A (ja) * 2006-10-03 2010-02-25 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤として有用なインダゾリル誘導体
CN101568529A (zh) 2006-12-22 2009-10-28 诺瓦提斯公司 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物
PE20081636A1 (es) 2007-01-26 2009-01-10 Smithkline Beecham Corp Inhibidores de antranilamida para aurora quinasa
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
UA104849C2 (uk) 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
CA2707989A1 (en) 2007-12-07 2009-06-11 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
AU2009238590A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
US8618099B2 (en) 2008-09-02 2013-12-31 Ataxion, Inc. Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010061903A1 (ja) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
JPWO2010092962A1 (ja) 2009-02-12 2012-08-16 アステラス製薬株式会社 へテロ環誘導体
TW201038567A (en) 2009-03-27 2010-11-01 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
JP2012528174A (ja) 2009-05-27 2012-11-12 アボット・ラボラトリーズ キナーゼ活性のピリミジン阻害剤
WO2010144416A1 (en) 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
LT3141252T (lt) * 2009-06-17 2018-11-12 Vertex Pharmaceuticals Inc. Gripo virusų replikacijos inhibitoriai
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
ES2483594T3 (es) 2009-07-15 2014-08-06 Abbott Laboratories Pirrolopirazinas inhibidoras de quinasas
ES2539170T3 (es) 2010-01-12 2015-06-26 Ab Science Inhibidores de quinasas de oxazol
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
CA2807226A1 (en) * 2010-08-19 2012-02-23 F.Hoffmann-La Roche Ag Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs)
PT2616465E (pt) 2010-09-13 2016-03-09 Novartis Ag Triazino-oxadiazoles
BR112013020641B1 (pt) 2011-02-25 2021-11-03 Yuhan Corporation Composto, composição farmacêutica, processos para a preparação de composto e respectivo uso ou de seu sal farmaceuticamente aceitável
CA2840883C (en) 2011-07-07 2019-07-16 Merck Patent Gmbh Substituted azaheterocycles
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
NZ746607A (en) * 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
US20220185795A1 (en) * 2019-03-11 2022-06-16 Ptc Therapeutics, Inc. Compound form having enhanced bioavailability and formulations thereof

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978055A (en) * 1973-09-20 1976-08-31 Delalande S.A. Arylamino pyrimidinic derivatives
CN1155281A (zh) * 1994-08-13 1997-07-23 株式会社柳韩洋行 新的嘧啶衍生物及其制备方法
CN1349528A (zh) * 1999-03-06 2002-05-15 阿斯特拉曾尼卡有限公司 嘧啶化合物
CN1429222A (zh) * 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
US20040097503A1 (en) * 2000-12-12 2004-05-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20040043388A1 (en) * 2001-03-02 2004-03-04 Come Jon H. Three hybrid assay system
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
CN101679432A (zh) * 2006-10-19 2010-03-24 西格诺药品有限公司 杂芳基化合物、其组合物及其作为蛋白激酶抑制剂的用途
WO2010002985A1 (en) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
US20110190239A1 (en) * 2008-07-01 2011-08-04 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
WO2011121418A1 (en) * 2010-03-31 2011-10-06 Palobiofarma, S.L. 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
WO2012050884A2 (en) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
WO2012078777A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ACS: "RN：396135-22-1", 《STN-REGISTRY数据库》 *
ACS: "RN：79871-84-4", 《STN-REGISTRY数据库》 *
ACS: "RN：79871-85-5", 《STN-REGISTRY数据库》 *
DANIEL MOSER，等: "Dual-Target Virtual Screening by Pharmacophore Elucidation and Molecular Shape Filtering", 《ACS MEDICINAL CHEMISTRY LETTERS》 *
HOWARD BREGMAN，等: "Identification of a Potent, State-Dependent Inhibitor of Nav1.7 with Oral Efficacy in the Formalin Model of Persistent Pain", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
JUNJI MIYATA，等: "Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
KIRK E. HEVENER，等: "Discovery of a Novel and Potent Class of F. tularensis Enoyl-Reductase (FabI) Inhibitors by Molecular Shape and Electrostatic Matching", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
MARK SABAT，等: "The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck)", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
PHUONG T. LE，等: "Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
THIRUMURTHY MADHAVAN，等: "3D-QSAR studies of JNK1 inhibitors utilizing various alignment methods", 《CHEMICAL BIOLOGY & DRUG DESIGN》 *
YAO MA，等: "Combinatorial Synthesis of Substituted Biaryls and Heterocyclic Arylamines", 《JOURNAL OF COMBINATORIAL CHEMISTRY》 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602775A (zh) * 2016-01-14 2018-09-28 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
CN108602775B (zh) * 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
CN109988172A (zh) * 2019-01-10 2019-07-09 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
CN113784757A (zh) * 2019-01-15 2021-12-10 Ptc医疗公司 治疗急性髓性白血病的方法
CN113710670A (zh) * 2019-02-28 2021-11-26 Ptc医疗公司 治疗多发性骨髓瘤的方法
CN113853374A (zh) * 2019-03-11 2021-12-28 Ptc医疗公司 具有增强的生物利用度的化合物形式及其制剂
CN113853374B (zh) * 2019-03-11 2025-02-28 Ptc医疗公司 具有增强的生物利用度的化合物形式及其制剂
CN114096537A (zh) * 2019-03-27 2022-02-25 Ptc医疗公司 肉瘤治疗方法的有用组合
CN114096537B (zh) * 2019-03-27 2025-01-10 Ptc医疗公司 肉瘤治疗方法的有用组合
WO2020200209A1 (zh) * 2019-04-02 2020-10-08 成都海创药业有限公司 芳香胺类化合物及其在制备ar和brd4双重抑制剂和调控剂中的用途
AU2020251673B2 (en) * 2019-04-02 2023-09-28 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of AR and BRD4 dual inhibitors and regulators

Also Published As

Publication number Publication date
ZA201503642B (en) 2020-10-28
CU24387B1 (es) 2019-03-04
US11180483B2 (en) 2021-11-23
JP6617186B2 (ja) 2019-12-11
MA38208B1 (fr) 2021-12-31
US20200024260A1 (en) 2020-01-23
AU2013348009A1 (en) 2015-06-04
EP2922828A4 (en) 2016-07-27
PE20151413A1 (es) 2015-10-23
AU2013348009B2 (en) 2018-05-17
IL238871A0 (en) 2015-07-30
EA031405B1 (ru) 2018-12-28
TW201427972A (zh) 2014-07-16
EP2922828A2 (en) 2015-09-30
NI201500072A (es) 2016-01-18
UA118094C2 (uk) 2018-11-26
JP2020055815A (ja) 2020-04-09
MX2021009892A (es) 2021-09-14
JP2019031509A (ja) 2019-02-28
CA2892045C (en) 2022-05-31
NZ746607A (en) 2019-11-29
KR102275676B1 (ko) 2021-07-12
KR102356487B1 (ko) 2022-02-08
US20150315182A1 (en) 2015-11-05
JP6918898B2 (ja) 2021-08-11
BR112015011760A2 (pt) 2017-07-11
EA035349B1 (ru) 2020-05-29
CR20150294A (es) 2015-08-20
TWI623531B (zh) 2018-05-11
BR112015011760B1 (pt) 2022-12-06
MX385385B (es) 2025-03-18
US10428050B2 (en) 2019-10-01
PT2922828T (pt) 2020-10-12
MX2015006469A (es) 2015-10-29
KR20210088740A (ko) 2021-07-14
NZ708909A (en) 2019-11-29
JP6412503B2 (ja) 2018-10-24
SA517381847B1 (ar) 2021-07-17
WO2014081906A2 (en) 2014-05-30
SG11201503982XA (en) 2015-06-29
CN111423417B (zh) 2022-11-15
EA201590992A1 (ru) 2015-11-30
JP2016504290A (ja) 2016-02-12
IL265253A (en) 2019-05-30
WO2014081906A3 (en) 2014-07-17
SG10201600149VA (en) 2016-02-26
CA2892045A1 (en) 2014-05-30
EP2922828B1 (en) 2020-07-08
DK2922828T3 (da) 2020-08-31
PH12015501130A1 (en) 2015-08-03
ES2821529T3 (es) 2021-04-26
IL238871B (en) 2019-03-31
CL2015001377A1 (es) 2016-02-19
KR102455889B1 (ko) 2022-10-17
AR093579A1 (es) 2015-06-10
KR20220016305A (ko) 2022-02-08
PL2922828T3 (pl) 2020-12-28
US20220064150A1 (en) 2022-03-03
AU2013348009C1 (en) 2019-08-08
ECSP15019948A (es) 2016-01-29
KR20220143164A (ko) 2022-10-24
HK1215032A1 (zh) 2016-08-12
EA201890142A1 (ru) 2018-06-29
CN111423417A (zh) 2020-07-17
KR20150086345A (ko) 2015-07-27
CU20150053A7 (es) 2015-11-27
PH12015501130B1 (en) 2023-01-27

Similar Documents

Publication Publication Date Title
CN111423417B (zh) 取代的反向嘧啶Bmi-1抑制剂
JP6524094B2 (ja) 置換ピリミジンＢｍｉ−１阻害剤
US9975878B2 (en) Substituted triazine BMI-1 inhibitors
HK40034027B (en) Substituted reverse pyrimidine bmi-1 inhibitors
HK40034027A (en) Substituted reverse pyrimidine bmi-1 inhibitors
HK1226057B (zh) 取代的嘧啶bmi-1抑制剂
BR112016004511B1 (pt) Composto, composto ou uma forma do mesmo, uso de um composto ou forma do mesmo, e composição farmacêutica para uso no tratamento de um câncer mediado por bmi-1

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1215032

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150916

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1215032

Country of ref document: HK